Toxicology – Bradycardia Toxidrome

Definition

Bradycardia is a heart rate that is slower than expected for the patient’s age and physiologic condition.

In adults, it is conventionally defined as a resting heart rate <60 beats/min, although the clinical importance depends more on whether the slow rate is causing poor perfusion or hemodynamic instability.

A patient with an asymptomatic slow heart rate and adequate perfusion does not necessarily require treatment.

Pathophysiology

Toxicologic bradycardia can result from several mechanisms:

• β-adrenergic receptor blockade
• Calcium-channel blockade
• Cardiac sodium-channel blockade
• Increased cholinergic activity
• Increased vagal tone
• Suppression of sympathetic outflow
• Direct myocardial depression
• Abnormal cardiac conduction

Nontoxicologic mechanisms include:

• Hypoxia
• Hypothermia
• Hyperkalemia
• Hypermagnesemia
• Myocardial ischemia/infarction
• Increased intracranial pressure

Important Toxicologic Causes

Beta-blockers

• Bradycardia
• Hypotension
• AV block
• Myocardial depression
• CNS depression or seizures with some agents

Severe poisoning can produce cardiogenic shock.

Calcium-channel blockers

• Bradycardia
• Hypotension
• AV block
• Myocardial depression

A useful metabolic clue is hyperglycemia, particularly in severe calcium-channel blocker poisoning.

Digoxin and other cardiac glycosides

• Bradycardia or AV block
• Nausea and vomiting
• Visual disturbances
• Hyperkalemia in significant acute poisoning
• Numerous atrial and ventricular dysrhythmias

Clonidine and imidazolines

• Bradycardia
• Hypotension
• CNS depression
• Miosis
• Respiratory depression

This presentation may resemble opioid poisoning.

Opioids

• CNS depression
• Respiratory depression
• Miosis
• Bradycardia in significant poisoning

Cholinergic agents

Examples include organophosphate and carbamate insecticides.

Typical associated findings include:

• Salivation
• Lacrimation
• Bronchorrhea
• Vomiting and diarrhea
• Urination
• Miosis
• Sweating

Nicotinic manifestations such as fasciculations and muscle weakness particularly support organophosphate/carbamate toxicity.

Other Possible Toxicologic Causes

Bradycardia can also occur with selected exposures involving:

• Baclofen
• Lithium
• Antiarrhythmic drugs
• Certain mushrooms
• Tetrodotoxin
• Saxitoxin
• Other cardiotoxic or neurotoxic agents

The accompanying toxidrome is usually more useful than bradycardia alone for identifying the cause.

Clinical Features

The major question is whether bradycardia is causing inadequate cardiac output.

Concerning findings include:

• Hypotension
• Altered mental status
• Syncope
• Chest discomfort
• Signs of shock
• Pulmonary edema
• Poor peripheral perfusion

Severe poisoning may progress to:

• High-grade AV block
• Ventricular dysrhythmias
• Cardiogenic shock
• Cardiac arrest

Diagnostic Clues

Miosis + respiratory/CNS depression

→ opioid, clonidine, or imidazoline exposure

Bradycardia + hyperglycemia

→ consider calcium-channel blocker toxicity

Bradycardia + hypoglycemia/CNS toxicity

→ may suggest severe beta-blocker poisoning

Bradycardia + vomiting + visual disturbance + hyperkalemia

→ consider digoxin toxicity

Bradycardia + miosis + bronchorrhea + secretions

→ consider cholinergic poisoning

Evaluation

Important investigations include:

• 12-lead ECG
• Continuous cardiac monitoring
• Blood pressure and perfusion assessment
• Pulse oximetry
• Blood glucose
• Electrolytes
• Renal function

Depending on the suspected exposure, additional testing may include:

• Potassium, magnesium and calcium
• Digoxin concentration
• Cholinesterase testing
• Targeted toxicant concentrations
• Acetaminophen concentration when an intentional or unknown overdose is possible

Routine broad urine drug screening is usually less useful than targeted testing based on the clinical toxidrome.

ECG Findings

The ECG helps identify both the severity and possible mechanism.

Possible abnormalities include:

• Sinus bradycardia
• PR prolongation
• AV block
• QRS widening
• QT abnormalities
• Ventricular dysrhythmias

QRS widening should raise concern for an additional sodium-channel-blocking effect rather than simple sinus-node suppression alone.

Management

Treatment is determined by perfusion and underlying cause, not simply by the heart-rate number.

Initial priorities include:

• Airway and ventilation when required
• IV access
• Continuous cardiac monitoring
• Correction of hypoxia
• Correction of important electrolyte or glucose abnormalities
• Appropriate IV fluids when hypovolemia is present

Excessive fluid administration should be avoided when significant myocardial depression is suspected.

Atropine

Atropine may be attempted for symptomatic bradycardia, particularly when increased vagal activity or AV-nodal dysfunction contributes.

However, atropine may be ineffective in severe toxicologic bradycardia, especially with major beta-blocker or calcium-channel blocker poisoning.

Failure of atropine should prompt treatment directed at the responsible toxicant rather than repeated reliance on atropine alone.

Cause-Specific Therapy

Beta-blocker poisoning

• Supportive cardiovascular care
• Vasopressors when necessary
• High-dose insulin euglycemia therapy for severe cardiotoxicity
• Glucagon may be considered, although contemporary practice generally regards it as an adjunct rather than the central therapy.

Calcium-channel blocker poisoning

• IV calcium
• High-dose insulin euglycemia therapy
• Vasopressor support
• Additional rescue therapies in refractory cases

Digoxin toxicity

• Digoxin immune Fab for severe poisoning

Opioid toxicity

• Naloxone when clinically significant respiratory depression is present
• Ventilatory support when necessary

Organophosphate/carbamate toxicity

• Atropine for clinically important muscarinic manifestations
• Pralidoxime is particularly relevant to significant organophosphate poisoning.

Refractory Bradycardia and Shock

When severe bradycardia remains associated with inadequate perfusion despite initial treatment, management may require:

• Vasopressors
• Toxicant-specific antidotal therapy
• Temporary cardiac pacing in selected cases
• Advanced mechanical circulatory support for refractory cardiogenic shock

Importantly, electrical pacing may restore the heart rate without adequately correcting drug-induced myocardial contractile failure, so the underlying poisoning must still be treated.

Decontamination

Older sources recommended routine gastric lavage for poisoned patients with bradycardia. This is not standard modern management.

Activated charcoal may be considered after selected recent ingestions when:

• The substance is adsorbed by charcoal.
• The expected benefit is meaningful.
• The airway is intact or protected.

Decontamination should never delay stabilization of an unstable patient.

Key Points

• Treat symptomatic bradycardia and poor perfusion, not the heart-rate number alone.
• Major toxicologic causes include beta-blockers, calcium-channel blockers, digoxin, clonidine/imidazolines, opioids, and cholinergic agents.
• Bradycardia + hyperglycemia → think calcium-channel blocker toxicity.
• Bradycardia + hypoglycemia/CNS effects → consider beta-blocker toxicity.
• Bradycardia + GI/visual symptoms + hyperkalemia → think digoxin.
• Bradycardia + miosis + respiratory depression → think opioids or clonidine/imidazolines.
• Bradycardia + bronchorrhea/secretions → think cholinergic poisoning.
• Atropine can be attempted in symptomatic bradycardia but may be ineffective in severe cardiotoxic poisoning.
• Severe beta-blocker and calcium-channel blocker poisoning often requires high-dose insulin therapy plus hemodynamic support.
• ECG and continuous cardiac monitoring are essential in clinically significant toxicologic bradycardia.